ライフサイエンスコーパス: antimitotic

1 vented, because C/EBPalpha and PPARgamma are antimitotic.

2 perproliferation, indicating that ZA was not antimitotic.

3 sents a unique edge over the other available antimitotics.

4 We hereby report that, unlike other antimitotics, AB-5 is extremely well tolerated by mice w

5 a) promotes cellular differentiation and has antimitotic activities involving cell cycle arrest at G(

6 of 7,11-epi-thyrsiferol (4), (b) compare the antimitotic activities of thyrsiferol (2), Delta15,28-de

7 e benzimidazole series exhibited distinctive antimitotic activity as evidenced by blockade of bipolar

8 ptophycin 1 exerts its antiproliferative and antimitotic activity by binding reversibly and with high

9 High-content screening of this library for antimitotic activity followed by chemical modification i

10 altering replication and possessing a strong antimitotic activity in human cancer cell lines.

11 The observed antimitotic activity is due to the binding of HTI-286 to

12 ration and differentiation suggests that the antimitotic activity of NGF may be obligatory for differ

13 promising new tubulin-binding compound with antimitotic activity that has potential for treating neo

14 gen metabolite 2-methoxyestradiol has modest antimitotic activity that may result from a weak interac

15 sues, C/EBP alpha is also associated with an antimitotic activity.

16 enous mammalian catabolite of estradiol with antimitotic activity.

17 K substrates in Xenopus egg extracts and has antimitotic activity.

18 hesis of the potent microtubule-stabilizing, antimitotic agent (+)-discodermolide is described.

19 fanilamide (GB-II-5), is a potent, selective antimitotic agent against kinetoplastid parasites.

20 Topical treatments of grafted HSE with the antimitotic agent colchicine select for keratinocyte pro

21 The interaction of the antimitotic agent estramustine with bovine microtubule p

22 TI-286, a synthetic analogue of the peptidic antimitotic agent hemiasterlin, to tubulin is proposed.

23 ocking proliferation of these cells with the antimitotic agent mitomycin C.

24 neration synthesis of the exceedingly potent antimitotic agent N(14)-desacetoxytubulysin H (1) as wel

25 nblastine, or dolastatin 10 (another peptide antimitotic agent that depolymerizes microtubules) but w

26 Vinblastine is an antimitotic agent that has been used extensively in canc

27 potency against GC3/c1, LYC5 cells, and the antimitotic agent vincristine.

28 lb/c mice, suggesting that 3c could be a new antimitotic agent with clinical potential.

29 model, suggesting that 3b is a promising new antimitotic agent with clinical potential.

30 model, suggesting that 4l is a promising new antimitotic agent with clinical potential.

31 Paclitaxel (Taxol), a naturally occurring antimitotic agent, has shown significant cell-killing ac

32 Paclitaxel (Taxol), a naturally occurring antimitotic agent, has shown significant cell-killing ac

33 B-II-5, compound 3), a new antikinetoplastid antimitotic agent, have been synthesized and evaluated.

34 riety of stimuli, including the DNA-cleaving antimitotic agent, neocarzinostatin (NCS).

35 natural product hemiasterlin and is a potent antimitotic agent.

36 ed hydroxyphenstatin, a potent antitumor and antimitotic agent.

37 was also inhibited by bullatacin and various antimitotic agents (podophyllotoxin, vinblastine, and co

38 By suppressing APC(Cdc20), antimitotic agents activate the spindle-assembly checkpo

39 agent in those tumors resistant to existing antimitotic agents and those dependent on Hedgehog pathw

40 Taxol and other antimitotic agents are frontline chemotherapy agents but

41 nd-specific reversibility characteristics of antimitotic agents contribute to interactions between ce

42 ifiable, compound-specific characteristic of antimitotic agents in general.

43 inhibition was specifically synergistic with antimitotic agents in killing cancer cells that had unde

44 Alternatively, exposure to antimitotic agents just after neural tube closure could

45 remarkably also reverse tumor resistance to antimitotic agents mediated via the P-glycoprotein efflu

46 D30 monoclonal antibody cAC10, linked to the antimitotic agents monomethyl auristatin E (MMAE) or F (

47 one and in combination with DNA-damaging and antimitotic agents on human cancer cells.

48 Combinations of EM with other antimitotic agents such as docetaxel are synergistic in

49 dentify putative biomarkers of resistance to antimitotic agents such as paclitaxel and monomethyl-aur

50 ally distinct from those of well-established antimitotic agents such as taxol.

51 Chemotherapy of prostate cancer with antimitotic agents such as vinblastine and doxorubicin i

52 Compounds of this series are promising novel antimitotic agents that have the potential for treating

53 Antimitotic agents that interfere with microtubule forma

54 Paclitaxel (Taxol) and the epothilones are antimitotic agents that promote the assembly of mammalia

55 sulfonamides are a novel promising class of antimitotic agents with clinical development potential.

56 yins A and B and eleutherobin (coral-derived antimitotic agents) and of compound 1, an analogue of sa

57 lin binding of the Vinca alkaloids and other antimitotic agents, (2) proximity to stretches of amino

58 (TP53, best known as p53) in the presence of antimitotic agents, as determined by cytofluorometric an

59 and phomopsin A have been found to be potent antimitotic agents, causing cell death at picomolar or l

60 ctiveness of this drug exceeds that of other antimitotic agents, suggesting it may have an additional

61 uld affect the sensitivity of tumor cells to antimitotic agents.

62 ld enhance traditional and second-generation antimitotic agents.

63 es with greater efficacy than currently used antimitotic agents.

64 agents that differed in this respect was the antimitotic agents.

65 poptosis in neuroblastoma cells treated with antimitotic agents.

66 ermeability relative to many clinically used antimitotic agents.

67 de a molecular marker to predict response to antimitotic agents.

68 ase in caspase-3/7 activation in response to antimitotic agents.

69 s and cancers that are resistant to standard antimitotic agents.

70 n of a series of triazole-based compounds as antimitotic agents.

71 d a great deal of interest as a new class of antimitotic agents.

72 Several semisynthetic antimitotic alkaloids are emerging as possible candidate

73 estradiol, 2-Methoxyestradiol (2ME2), is an antimitotic and antiangiogenic cancer drug candidate tha

74 rolo[2,3-d]pyrimidin-2-amines, which possess antimitotic and antitumor activities against antimitotic

75 ese events is critical because C/EBPalpha is antimitotic and its expression prematurely would block t

76 taxanes represent a combination of specific antimitotic and nonspecific antiangiogenic effects.

77 f promising antiproliferative compounds with antimitotic and potential VDA properties.

78 Both the antimitotic and the antiphenotypic effects are reversibl

79 ABT-751 is an antimitotic and vascular disrupting agent with potent pr

80 The antimitotic anti-cancer drugs, including taxol, perturb

81 nthetic member of the cryptophycin family of antimitotic antitumor agents that is currently undergoin

82 Treatment of ovarian carcinomas with the antimitotic antitumor drug paclitaxel is highly efficaci

83 e TCRP antimitotic cluster were confirmed as antimitotic based on independent assays, thus establishi

84 C/EBPalpha, which is antimitotic, becomes centromere-associated much later in

85 broad spectrum of activity of currently used antimitotics by significant toxicities in normal dividin

86 studied a naturally occurring small-molecule antimitotic called diazonamide A.

87 Current antimitotic cancer chemotherapy based on vinca alkaloids

88 ine and other microtubule inhibitors used as antimitotic cancer drugs characteristically promote the

89 flow to quantify cell-cycle effects of three antimitotic cancer drugs over 8 d in HT-1080 fibrosarcom

90 CR leukemia cell line, which is resistant to antimitotic cancer drugs vincrisitine and paclitaxel thr

91 of mitosis are attractive targets for novel antimitotic cancer therapies.

92 potential targets for the discovery of novel antimitotic cancer therapies.

93 ta-tubulin isotypes, the primary targets for antimitotic chemotherapeutic drugs like taxanes, has imp

94 Vincristine, along with other antimitotic chemotherapeutic drugs, produces a periphera

95 tion will facilitate rational improvement of antimitotic chemotherapy and perhaps cytotoxic chemother

96 aploid cells and limits the effectiveness of antimitotic chemotherapy drugs.

97 potential function for p53 in the outcome of antimitotic chemotherapy.

98 ly, 113 of the 117 hit compounds in the TCRP antimitotic cluster were confirmed as antimitotic based

99 in human cells, suggesting the potential for antimitotic combination therapy.

100 colchicinoids are analogues of the important antimitotic compound (-)-colchicine 1.

101 yl-6-phenyl-4(1H)-pyridinone (IKP-104) is an antimitotic compound which inhibits polymerization and i

102 raene lactone marine natural product, was an antimitotic compound, and we confirmed this prediction.

103 (R,S)-1 is a potent antimitotic compound.

104 19 595 compound library and identified novel antimitotic compounds based on clustering analysis of th

105 asure and characterize cellular responses to antimitotic compounds or siRNAs.

106 s are a group of novel microtubule-targeted, antimitotic compounds that have a paclitaxel-like, assem

107 Several structurally diverse antimitotic compounds, including the epothilones, compet

108 ich is located near the binding site of some antimitotic compounds, reduce microtubule dynamicity gre

109 pened the way to investigation and design of antimitotic compounds.

110 otential interest to explore combinations of antimitotic coumarins with other chemotherapeutic agents

111 The antimitotic depsipeptide cryptophycin 1 (CP1) was compar

112 The antimitotic depsipeptide dolastatin 15 was radiolabeled

113 clinical trials, is a peptide analog of the antimitotic depsipeptide dolastatin 15.

114 spases and CAD may be an important aspect of antimitotic drug action.

115 ell proliferation by central delivery of the antimitotic drug arabinofuranosyl cytidine (AraC) blunte

116 n after depletion of mitotic cells using the antimitotic drug cytosine-beta-D-arabinofuranoside.

117 ins that have great potential as targets for antimitotic drug development.

118 The antimitotic drug IKP104 [2-(4-fluorophenyl)-1-(2-chloro-

119 ined whether the single-cell response to the antimitotic drug paclitaxel (Ptx) was the same in tumors

120 We have characterized the effects of the antimitotic drug paclitaxel (Taxol(TM)) on the Ca(2+) si

121 lines, including cell lines resistant to the antimitotic drug paclitaxel and to other aurora kinase i

122 Halichondrin B is an antimitotic drug that inhibits microtubule assembly.

123 totic arrest contributes to tumorigenesis or antimitotic drug toxicity is not well defined.

124 pite the common state of arrest, the various antimitotic drug treatments resulted in differences in t

125 s mutants that survive in the presence of an antimitotic drug, hemiasterlin, we identified eight stro

126 o by cyclin-dependent kinase 1 (CDK1) during antimitotic drug-induced mitotic arrest and also in norm

127 (doxorubicin, dacarbazine, temozolamide) or antimitotic drugs (paclitaxel and docetaxel) in a variet

128 hydroxyurea; and inhibition of growth by the antimitotic drugs benomyl and thiabendazole.

129 Mitotic arrest induced by antimitotic drugs can cause apoptosis or p53-dependent c

130 indings in terms of the variable efficacy of antimitotic drugs in cancer chemotherapy.

131 We conclude that variation in sensitivity to antimitotic drugs in drug-naive cell lines is governed m

132 binding site(s) for peptide and depsipeptide antimitotic drugs may consist of a series of overlapping

133 of chemotherapy might be due to an action of antimitotic drugs on mitochondrial function and an inter

134 timitotic kinesin-5 inhibitor and additional antimitotic drugs revealed strong induction of p53 after

135 regulation, as well as the mode of action of antimitotic drugs that disrupt normal microtubule behavi

136 Vinca alkaloids are antimitotic drugs that inhibit microtubule assembly and

137 otic arrest has proved clinically useful, as antimitotic drugs that interfere with proper chromosome-

138 The epothilones are naturally occurring antimitotic drugs that share with the taxanes a similar

139 This compound defines a novel class of antimitotic drugs that work through inhibition of src ki

140 nd thus how microtubule inhibitors and other antimitotic drugs ultimately elicit their lethal effects

141 Antimitotic drugs used in the chemotherapeutic treatment

142 eful as a marker to define susceptibility to antimitotic drugs, and encourage a revision in the curre

143 ely, Tbr2+ IPCs were selectively depleted by antimitotic drugs, known to suppress neurogenesis.

144 cells are depolymerized by cold, Ca(2+), or antimitotic drugs, neuronal microtubules are unusually s

145 d in terms of the cellular mode of action of antimitotic drugs, particularly the importance of microt

146 in in microtubule assembly and resistance to antimitotic drugs.

147 cells maintain a high efflux capability for antimitotic drugs.

148 e cytotoxic and antineoplastic properties of antimitotic drugs.

149 tic signaling and the mechanism of action of antimitotic drugs.

150 diverse roles in mitosis and are targets for antimitotic drugs.

151 interaction are distinct from those of other antimitotic drugs.

152 mitotic state of arrest generated by various antimitotic drugs.

153 e organization, assembly, and sensitivity to antimitotic drugs.

154 uring mitosis, and determines sensitivity to antimitotic drugs.

155 t a phenotypic and molecular level for three antimitotic drugs: paclitaxel, nocodazole, and an inhibi

156 dynamics, conformation, and interaction with antimitotic drugs; however, very little is known about t

157 riant in cortical neuroblasts transforms the antimitotic effect of PACAP into a promitogenic signal.

158 significantly decreased the proapoptotic and antimitotic effect of transfected or secreted SEMA3B on

159 The antimitotic effect was found to be due to the inhibition

160 lts in an antagonistic antiproliferative and antimitotic effect, possibly due to the abrogation of Ta

161 letion of the polyaspartyl end abolished the antimitotic effect.

162 amides, the active compounds did not display antimitotic effects against Leishmania.

163 in with an IC(50) of 6.9 microM and displays antimitotic effects in cultured T. brucei as assessed by

164 ne in rabbit eyelid, taking advantage of the antimitotic effects of doxorubicin on satellite cell div

165 sion results in increased sensitivity to the antimitotic effects of okadaic acid.

166 n of calpains but did not interfere with the antimitotic effects of Taxol on microtubules, nor did it

167 The antimitotic effects of the widely used cancer chemothera

168 , which are the amino analogues of cytotoxic antimitotic flavonoids.

169 Analogs of the antimitotic herbicide oryzalin (3,5-dinitro-N4,N4-di-n-p

170 Ustiloxins A-F are antimitotic heterodetic cyclopeptides containing a 13-me

171 totic arrest and mitotic slippage induced by antimitotics in tumors.

172 subventricular zone quickly rebounds from an antimitotic insult by increasing proliferation and reple

173 aging in human cancer cells responding to an antimitotic kinesin-5 inhibitor and additional antimitot

174 Leiodermatolide is an antimitotic macrolide isolated from the marine sponge Le

175 combretastatin A-4 or with an analog of the antimitotic marine peptide diazonamide A (both the analo

176 e antitumor drugs vinblastine and taxol, the antimitotic mechanism of action of estramustine may be d

177 spindles, consistent with the tubulin-based antimitotic mechanism of halichondrin B.

178 Thus, like the antimitotic mechanisms of action of the antitumor drugs

179 in vivo anticancer effects via tubulin-based antimitotic mechanisms, which are similar or identical t

180 tal radial glial disruption by delivering an antimitotic [methylazoxy methanol (MAM)] to pregnant fer

181 This protein is a promising target for antimitotic monomethyl auristatin E (MMAE)-based antibod

182 t inhibitors, an asymmetric synthesis of the antimitotic natural product, ustiloxin D, has been compl

183 activities comparable to those of the potent antimitotic natural products colchicine, podophyllotoxin

184 ies nearly comparable to those of the potent antimitotic natural products colchicine, podophyllotoxin

185 vity nearly comparable to that of the potent antimitotic natural products colchicine, podophyllotoxin

186 ad effects comparable to those of the potent antimitotic natural products podophyllotoxin and combret

187 portant targets for the design of drugs with antimitotic or antineurodegenerative effects.

188 cancer, and demonstrate that TTP induces an antimitotic pathway that is diminished in cancer.

189 ide cryptophycin 1 (CP1) was compared to the antimitotic peptide dolastatin 10 (D10) as an antiprolif

190 Dolastatin 10 is a highly cytotoxic antimitotic peptide in phase II clinical trials.

191 Hemiasterlin is a potent antimitotic peptide that interferes with microtubule dyn

192 rated that hemiasterlin resembles most other antimitotic peptides in noncompetitively inhibiting the

193 In addition, we speculate that antimitotic peptides mimic the interaction of stathmin w

194 for the synthesis of the tubulysin family of antimitotic peptides was developed.

195 structures observed with vinca alkaloids and antimitotic peptides.

196 t inactivates, specifically during M phase, "antimitotic" phosphatases directed against phosphorylati

197 ecific alliance to produce the highly potent antimitotic phytotoxin rhizoxin.

198 c ring generally decreases antiparasitic and antimitotic potency, but placement of a dibutyl substitu

199 Both PM050489 and PM060184 show antimitotic properties in human tumor cells lines at sub

200 Given the antimitotic properties of cisplatin, we examined whether

201 s has functional significance related to the antimitotic properties of the compound.

202 nd determined that only Fatostatin possessed antimitotic properties.

203 mportant implications for the development of antimitotic regimens that target this process.

204 apy cooperates synergistically with existing antimitotic regimens, enabling efficacy of subtherapeuti

205 rol: the promitotic response to cAMP and the antimitotic response to the Nf1 tumor suppressor.

206 antimitotic and antitumor activities against antimitotic-sensitive as well as resistant tumor cells.

207 TGF-beta-induced antimitotic signals are highly regulated during cell pro

208 Antimitotic spindle poisons are among the most important

209 d without pre-degeneration, purification or antimitotic steps.

210 STARD9 is a mitotic kinesin and a potential antimitotic target.

211 ecessary for spindle assembly, and potential antimitotic targets, we performed a proteomic and geneti

212 Consistent with antimitotics that inhibit the dynamic instability of tub

213 tives merit further examination as potential antimitotic therapeutics, specifically for brain cancers

214 silencing and its potential as a target for antimitotic therapies.

215 if targeted, could enhance responsiveness to antimitotic therapy.

216 mitotic arrest may promote tumorigenesis and antimitotic toxicity by provoking DNA damage.

217 ds (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division

218 Here we show that after antimitotic treatment with cytosine-beta-D-arabinofurano

219 been strongly attenuated are given a similar antimitotic treatment, recovery is limited to the reduce

220 After cessation of antimitotic treatment, recovery of neurogenesis was para

221 of immature precursors and neuroblasts by an antimitotic treatment, SVZ astrocytes divide to generate

222 activated stem cells that are eliminated by antimitotic treatment.

223 The sponge-derived antimitotic tripeptide hemiasterlin was previously shown

224 se arrest and potentiates the effects of the antimitotics vincristine and vinblastine in cell culture

225 pindle assembly checkpoint proteins and that antimitotics with different mechanisms trigger very simi

226 thereby interference by C/EBPalpha (which is antimitotic) with mitotic clonal expansion, an essential